Antibody formulation

Details Antibody formulation Antibody formulation

2006-01-31

2006-01-31

Chan, Christina (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S141100, C424S152100, C424S154100, C424S173100, C530S388730

Reexamination Certificate

active

06991790

ABSTRACT:
A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of antibody not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.5 to about 6.0, a surfactant and a polyol is described, along with uses for such a formulation.

REFERENCES:
patent: 4093606 (1978-06-01), Coval
patent: 4457916 (1984-07-01), Hayashi et al.
patent: 4499073 (1985-02-01), Tenold
patent: 4877608 (1989-10-01), Lee et al.
patent: 4940782 (1990-07-01), Rup et al.
patent: 5032405 (1991-07-01), Huang et al.
patent: 5096885 (1992-03-01), Pearlman et al.
patent: 5147637 (1992-09-01), Wright et al.
patent: 5149653 (1992-09-01), Roser
patent: 5215743 (1993-06-01), Singh et al.
patent: 5262296 (1993-11-01), Ogawa et al.
patent: 5307640 (1994-05-01), Fawzy et al.
patent: 5399670 (1995-03-01), Bhattacharya et al.
patent: 5506342 (1996-04-01), Reno et al.
patent: 5580856 (1996-12-01), Prestrelski et al.
patent: 5589167 (1996-12-01), Cleland et al.
patent: 5608038 (1997-03-01), Eibl et al.
patent: 5654403 (1997-08-01), Smith et al.
patent: 5730980 (1998-03-01), Ulevitch et al.
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5770700 (1998-06-01), Webb et al.
patent: B-30771/89 (1989-07-01), None
patent: 2138853 (1995-06-01), None
patent: 303746 (1989-02-01), None
patent: 391444 (1990-10-01), None
patent: 661060 (1995-07-01), None
patent: WO 89/09402 (1989-10-01), None
patent: WO 89/11297 (1989-11-01), None
patent: WO 90/11091 (1990-10-01), None
patent: WO 92/22653 (1992-12-01), None
patent: WO 94/11026 (1994-06-01), None
patent: WO 94/26302 (1994-11-01), None
patent: WO 96/41164 (1996-12-01), None
patent: WO 97/04801 (1997-02-01), None
patent: WO 97/04807 (1997-02-01), None
patent: WO 97/17087 (1997-05-01), None
US 5,036,049, 7/1991, Audhya et al. (withdrawn)
Akers, M., “Considerations in selecting antimicrobial preservative agents for parenteral product development.”,Pharmaceutical Technologypps. 36-40; 43-44;46 (May 1984).
Albelda et al., “Integrins and other cell adhesion molecules”FASEB-J4 (11) :2868-2880 (1990).
Arakawa et al., “Protein-Solvent Interactions in Pharmaceutical Formulations”Pharmaceutical Research8 (3):285-291 (1991).
Bam et al., “Stability of Protein Formulations: Investigation of Surfactant Effects by a Novel EPR Spectroscopic Technique”Pharm. Res. 12:2-11 (1995).
Beauvais et al., “Both Glassy State and Native Structure are Required for Storage Stability of Lyophilized Interleukin-1 Receptor Antagonist.”Pharm. Res. (Abstract #2007) 12 (9):S-80 (1995).
Bogard et al., “Practical considerations in the production, purification, and formulation of monoclonal antibodies for immunoscintigraphy and immunotherapy”Seminars in Nuclear Medicine19 (3) :202-220 (1989).
Chang and Fischer, “Development of an Efficient Single-Step Freeze-Drying Cycle for Protein Formulations”Pharm. Res. 12 (6) :831-837 (1995).
Chang et al., “Development of a Stable Freeze-dried Formulation of Recombinant Human Interleukin-1 Receptor Antagonist”Pharmaceutical Research13 (2):243-248 (1996).
Chang et al., “Nucelotide sequence of the alkaline phosphate gene ofEscherichia coli” Gene44:121-125 (1986).
Clarke et al., “Liability of Asparagine and Aspartic Acid Residues in Proteins and Peptides”Stability of Protein Pharmaceuticals, Part A: Chemical and Physical Pathways of Protein Degradation, T.J. Ahern and M.C. Manning, New York: Plenum Press, Chapter 1, pps. 1-29 (1992).
Cleland and Jones, “Development of Stable Protein Formulations for Microencapsulation in Biodegradable Polymers”Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 22:514-515 (1995).
Cleland et al., “Mechanisms of Nonionic Surfactant Stabilization of Proteins”Pharmaceutical Research(Abstract #BIOTEC 2012; Ninth Annual Meeting of the American Association of Pharmaceutical Scientists held in San Diego, CA on Nov. 6-10, 1994) 11(10 Suppl. ) :S73 (1994).
Cleland et al., “The Development of Stable Protein Formulations: A Close Look at Protein Aggregation, Deamidation, and Oxidation”Critical Reviews in Therapeutic Drug Carrier Systems10 (4) :307-377 (1993).
Draber et al., “Stability of Monoclonal IgM Antibodies Freeze-Dried in the Presence of Trehalose”Journal of Immunological Methods181 (1) :37-43 (1995).
Hernandez et al. “Role of neutrophils in ischemia-reperfusion-induced microvascular injury”Am. J. Physiol. 253 (3 Pt 2) :H699-H703 (1987).
Hildreth et al., “A Human Lymphocyte-associated Antigen Involved in Cell-mediated Lympholysis”European Journal of Immunology13:202-208 (1983).
Hildreth et al., “The human lymphocyte function-associated (HLFA) antigen and a related macrophage differentiation antigen (HMac-1) : functional effects of subunit-specific monoclonal antibodies”J. Immunol. 134:3272-3280 (1985).
Hynes, “Integrins: versatility, modulation, and signaling in cell adhesion”Cell69 (1) :11-25 (1992).
Izutsu et al., “The effects of additives on the stability of freeze-dried β-galactosidase stored at elevated temperature”Intl. J. Pharmaceutics71:137-146 (1991).
Jutila et al., “Inflammation-induced endothelial cell adhesion to lymphocyte, neutrophils, and monocytes”Transplantation48 (5):727-731 (1989).
Kossiakoff, A.A., “Tertiary Structure Is a Principal Determinant to Protein Deamidation”Science240:191-194 (1988).
Lam et al., “Microencapsulation of Recombinant Humanized Monoclonal Antibody for Local Delivery”American Association of Pharmaceutical Scientists, Western Regional Meeting, South San Francisco, CA(Abstract #F-22 and poster presented at the meeting) (Apr. 24-25, 1997).
Lam et al., “Microencapsulation of Recombinant Humanized Monoclonal Antibody for Local Delivery”Proceedings of the 24th International Symposium on Controlled Release of Bioactive Materials24: 759-760 (Jun. 15-19, 1997).
Lam et al., “Pitfalls in Development of Multi-Dose Liquid Formulations for Three Protein Pharmaceuticals”ACS National Meeting, New Orleans(Abstract #137 and slides presented) (Mar. 24-28, 1996).
Li et al., “Aggregation and Precipitation of Human Relaxin Induced by Metal-Catalyzed Oxidation”Biochemistry34 (17) :5762-5772 (1995).
Manning et al., “Stability of Protein Pharmaceuticals”Pharm. Res. 6(11) : 903-918 (1989).
Mileski et al., “Inhibition of CD18-dependent neutrophil adherence reduces organ injury after hemorrhagic shock in primates”Surgery108:206-212 (1990).
Nielsen, et al., “Stability of Freeze Dried Horseradish Peroxidase Conjuagted Monoclonal Antibodies Used in Diagnostic Serology”Journal of Immunoassay16(2) :183-197 (1995).
Novak et al., “The tolerance and safety of intravenously administered benzyl alcohol in methylprednisolone sodium succinate formulations in normal human subjects”Toxicology and Applied Pharmacology23 (1) :54-61 (Sep. 1972).
Pearlman et al., “Analysis of Protein Drugs”Peptide and Protein Drug Delivery, Vincent H. L. Lee, Marcel Dekker, Inc., Chapter 6, pps. 247-301 (1991).
Picken et al., “Nucleotide sequence of the gene for heat-stable enterotoxin II ofEscherichia coli” Infection and Immunity42 (1) :269-275 (1983).
Pikal et al., “The Effects of Formulation Variables on the Stability of Freeze-Dried Human Growth Hormone”Pharm. Res. 8 : 427-436 (1991).
Pikal, M., “Freeze-Drying of Proteins, Part 2: Formulation Selection”Biopharm. 3 (9) :26-30 (1990).
Rao and Kroon, “Orthoclone OKT3: Chemical Mechanisms and Functional Effects of Degradation of a Therapeutic Monoclonal Antibody”Stability and Characterization of Protein and Peptide Drugs: Case Histories, eds. John Wang and Rodney Pearlman, New York:Plenum Press pps. 135-158, chapter 4, (1993).
Reilly et al., “Oral delivery of antibodies: future pharmacokineti

Affiliated with

Also associated with

Rating

Antibody formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibody formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3559836